172 related articles for article (PubMed ID: 22198631)
21. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia.
Webber MM; Trakul N; Thraves PS; Bello-DeOcampo D; Chu WW; Storto PD; Huard TK; Rhim JS; Williams DE
Carcinogenesis; 1999 Jul; 20(7):1185-92. PubMed ID: 10383888
[TBL] [Abstract][Full Text] [Related]
22. Kidney, skeletal muscle and myocardium as potential target sites of Pygeum africanum toxicity in Wistar rats.
Duborija-Kovacevic N; Tomic Z
Rev Int Androl; 2019; 17(1):8-14. PubMed ID: 30691591
[TBL] [Abstract][Full Text] [Related]
23. Activity-guided isolation of an antiandrogenic compound of Pygeum africanum.
Schleich S; Papaioannou M; Baniahmad A; Matusch R
Planta Med; 2006 May; 72(6):547-51. PubMed ID: 16773539
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the therapeutic effect against benign prostatic hyperplasia and the active constituents from Epilobium angustifolium L.
Deng L; Zong W; Tao X; Liu S; Feng Z; Lin Y; Liao Z; Chen M
J Ethnopharmacol; 2019 Mar; 232():1-10. PubMed ID: 30529422
[TBL] [Abstract][Full Text] [Related]
25. Effects of Pygeum africanum extract (Tadenan) on vasoactive intestinal peptide receptors, G proteins, and adenylyl cyclase in rat ventral prostate.
Solano RM; García-Fernández MO; Clemente C; Querol M; Bellamy F; Sanchez-Chapado M; Prieto JC; Carmena MJ
Prostate; 2000 Nov; 45(3):245-52. PubMed ID: 11074527
[TBL] [Abstract][Full Text] [Related]
26. [Urological and sexual evaluation of treatment of benign prostatic disease using Pygeum africanum at high doses].
Carani C; Salvioli V; Scuteri A; Borelli A; Baldini A; Granata AR; Marrama P
Arch Ital Urol Nefrol Androl; 1991 Sep; 63(3):341-5. PubMed ID: 1723220
[TBL] [Abstract][Full Text] [Related]
27. Effect of Pygeum africanum tadenan on micturition and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone.
Yoshimura Y; Yamaguchi O; Bellamy F; Constantinou CE
Urology; 2003 Feb; 61(2):474-8. PubMed ID: 12597984
[TBL] [Abstract][Full Text] [Related]
28. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Dedhia RC; McVary KT
J Urol; 2008 Jun; 179(6):2119-25. PubMed ID: 18423748
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of a novel Prunus domestica extract (Sitoprin, CR002) on testosterone-induced benign prostatic hyperplasia (BPH) in male Wistar rats.
Swaroop A; Bagchi M; Kumar P; Preuss HG; Bagchi D
Toxicol Mech Methods; 2015; 25(9):653-64. PubMed ID: 26337762
[TBL] [Abstract][Full Text] [Related]
30. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies.
Mantovani F
Minerva Urol Nefrol; 2010 Dec; 62(4):335-40. PubMed ID: 20944533
[TBL] [Abstract][Full Text] [Related]
31. African plum and benign prostatic hypertrophy.
Strong KM
J Herb Pharmacother; 2004; 4(1):41-6. PubMed ID: 15273076
[No Abstract] [Full Text] [Related]
32. Combined extracts of Urtica dioica and Pygeum africanum in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses.
Krzeski T; Kazón M; Borkowski A; Witeska A; Kuczera J
Clin Ther; 1993; 15(6):1011-20. PubMed ID: 7509261
[TBL] [Abstract][Full Text] [Related]
33. Phytotherapeutic agents in the treatment of benign prostatic hyperplasia.
Dreikorn K
Curr Urol Rep; 2000 Aug; 1(2):103-9. PubMed ID: 12084323
[TBL] [Abstract][Full Text] [Related]
34. Effect of an integral suspension of Lepidium latifolium on prostate hyperplasia in rats.
Martínez Caballero S; Carricajo Fernández C; Pérez-Fernández R
Fitoterapia; 2004 Mar; 75(2):187-91. PubMed ID: 15030923
[TBL] [Abstract][Full Text] [Related]
35. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
[TBL] [Abstract][Full Text] [Related]
36. A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy.
Mathé G; Hallard M; Bourut CH; Chenu E
Biomed Pharmacother; 1995; 49(7-8):341-3. PubMed ID: 8562860
[No Abstract] [Full Text] [Related]
37. The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition.
Chen J; Rong N; Liu M; Xu C; Xiong Q; Lei Y
Toxicol Appl Pharmacol; 2021 Jan; 411():115384. PubMed ID: 33359661
[TBL] [Abstract][Full Text] [Related]
38. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
Rick FG; Abi-Chaker A; Szalontay L; Perez R; Jaszberenyi M; Jayakumar AR; Shamaladevi N; Szepeshazi K; Vidaurre I; Halmos G; Krishan A; Block NL; Schally AV
Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2617-22. PubMed ID: 23359692
[TBL] [Abstract][Full Text] [Related]
39. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity.
Schleich S; Papaioannou M; Baniahmad A; Matusch R
Planta Med; 2006 Jul; 72(9):807-13. PubMed ID: 16783690
[TBL] [Abstract][Full Text] [Related]
40. Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
Ub Wijerathne C; Park HS; Jeong HY; Song JW; Moon OS; Seo YW; Won YS; Son HY; Lim JH; Yeon SH; Kwun HJ
Biol Pharm Bull; 2017 Dec; 40(12):2125-2133. PubMed ID: 28943529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
